Clinical and Biological Features of 198 Patients Enrolled on CALGB Study 9111
| Characteristic at Diagnosis . | No. of Patients (%) . | ||
|---|---|---|---|
| G-CSG Group . | Placebo Group . | Total . | |
| 102 | 96 | 198 | |
| Age (yrs) | |||
| <30 | 45 (44) | 30 (31) | 75 (38) |
| 30-59 | 36 (35) | 46 (48) | 82 (41) |
| ≥60 | 21 (21) | 20 (21) | 41 (21) |
| Sex | |||
| Male | 61 (60) | 44 (46) | 105 (53) |
| Female | 41 (40) | 52 (54) | 93 (47) |
| Performance status (CALGB) | |||
| 0-1 | 80 (78) | 74 (78) | 154 (78) |
| 2-3 | 22 (22) | 21 (22) | 43 (22) |
| Mediastinal mass (chest radiograph) | |||
| Present | 7 (7) | 8 (9) | 15 (8) |
| Absent | 94 (93) | 85 (91) | 179 (92) |
| Lymphadenopathy (palpable) | |||
| Present | 32 (32) | 36 (40) | 68 (36) |
| Absent | 69 (68) | 54 (60) | 123 (64) |
| Splenomegaly (palpable) | |||
| Present | 27 (27) | 27 (29) | 54 (28) |
| Absent | 72 (73) | 66 (71) | 138 (72) |
| Leukocytes | |||
| <30,000/μL | 66 (65) | 57 (60) | 123 (62) |
| ≥30,000/μL | 36 (35) | 38 (40) | 74 (38) |
| Platelets | |||
| <50,000/μL | 53 (52) | 45 (48) | 98 (50) |
| ≥50,000/μL | 49 (48) | 49 (52) | 98 (50) |
| FAB subtype | |||
| L1 | 44 (44) | 39 (43) | 83 (44) |
| L2 | 37 (37) | 34 (37) | 71 (37) |
| L3 | 2 (2) | 2 (2) | 4 (2) |
| Other ALL | 11 (11) | 8 (9) | 19 (10) |
| AML/not ALL | 5 (5) | 8 (9) | 13 (7) |
| Immunophenotype | |||
| B or BMy | 61 (81) | 55 (77) | 116 (79) |
| T or TMy | 14 (19) | 16 (23) | 30 (21) |
| Cytogenetics | |||
| Ph+ | 12 (29) | 14 (28) | 26 (28) |
| Ph− | 30 (71) | 36 (72) | 66 (72) |
| Characteristic at Diagnosis . | No. of Patients (%) . | ||
|---|---|---|---|
| G-CSG Group . | Placebo Group . | Total . | |
| 102 | 96 | 198 | |
| Age (yrs) | |||
| <30 | 45 (44) | 30 (31) | 75 (38) |
| 30-59 | 36 (35) | 46 (48) | 82 (41) |
| ≥60 | 21 (21) | 20 (21) | 41 (21) |
| Sex | |||
| Male | 61 (60) | 44 (46) | 105 (53) |
| Female | 41 (40) | 52 (54) | 93 (47) |
| Performance status (CALGB) | |||
| 0-1 | 80 (78) | 74 (78) | 154 (78) |
| 2-3 | 22 (22) | 21 (22) | 43 (22) |
| Mediastinal mass (chest radiograph) | |||
| Present | 7 (7) | 8 (9) | 15 (8) |
| Absent | 94 (93) | 85 (91) | 179 (92) |
| Lymphadenopathy (palpable) | |||
| Present | 32 (32) | 36 (40) | 68 (36) |
| Absent | 69 (68) | 54 (60) | 123 (64) |
| Splenomegaly (palpable) | |||
| Present | 27 (27) | 27 (29) | 54 (28) |
| Absent | 72 (73) | 66 (71) | 138 (72) |
| Leukocytes | |||
| <30,000/μL | 66 (65) | 57 (60) | 123 (62) |
| ≥30,000/μL | 36 (35) | 38 (40) | 74 (38) |
| Platelets | |||
| <50,000/μL | 53 (52) | 45 (48) | 98 (50) |
| ≥50,000/μL | 49 (48) | 49 (52) | 98 (50) |
| FAB subtype | |||
| L1 | 44 (44) | 39 (43) | 83 (44) |
| L2 | 37 (37) | 34 (37) | 71 (37) |
| L3 | 2 (2) | 2 (2) | 4 (2) |
| Other ALL | 11 (11) | 8 (9) | 19 (10) |
| AML/not ALL | 5 (5) | 8 (9) | 13 (7) |
| Immunophenotype | |||
| B or BMy | 61 (81) | 55 (77) | 116 (79) |
| T or TMy | 14 (19) | 16 (23) | 30 (21) |
| Cytogenetics | |||
| Ph+ | 12 (29) | 14 (28) | 26 (28) |
| Ph− | 30 (71) | 36 (72) | 66 (72) |